Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
corrects the folding of the CFTR protein
|
| gptkbp:approves |
gptkb:2015
gptkb:FDA |
| gptkbp:can_be_used_with |
gptkb:Ivacaftor
|
| gptkbp:class |
gptkb:CFTR_modulators
|
| gptkbp:clinical_trial |
Phase 3 trials
~80% |
| gptkbp:developed_by |
gptkb:Vertex_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lumacaftor
|
| gptkbp:ingredients |
C22 H27 Cl F2 N2 O2 S
|
| gptkbp:is_used_for |
gptkb:cystic_fibrosis
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:Orkambi
|
| gptkbp:side_effect |
liver problems
respiratory symptoms gastrointestinal symptoms |
| gptkbp:type_of |
1005290-37-0
|
| gptkbp:bfsParent |
gptkb:CFTR_modulators
|
| gptkbp:bfsLayer |
4
|